Phaseline

Companies › Integrative Research Laboratories

Integrative Research Laboratories: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IRL757–Phase 1PARKINSON DISEASE (Disorder)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07461220IRL757Phase 1PARKINSON DISEASE (Disorder)NeurologyMay 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.